免疫检查点抑制剂治疗中缓解率作为生存替代终点的Meta回归分析
结果显示RR与PFS的关联较弱(R2=0.47;95%CI 0.03-0.77;P=0.001),RR与OS的关联更弱(R2=0.32;95%CI 0.02-0.76;P=0.01)。分层分析显示RR与非小细胞肺癌OS的关联极弱,与CTLA-4抑制剂PFS的关联中等。
要点
- RR与PFS、OS的替代关联均较弱,不支持将RR作为稳健替代终点。
- RR与PFS关联R2=0.47,RR与OS关联R2=0.32
- 需进一步研究评估RR在免疫检查点抑制剂治疗中的替代价值。
核心结论
- Meta回归分析显示RR与OS仅呈弱相关,支持未来进一步研究评估RR在免疫检查点抑制剂治疗患者中的替代性。
主要发现
- 全部数据集中,RR的log(OR)对PFS的log(HR)回归R2=0.47(95%CI 0.03-0.77;P=0.001)。
- 全部数据集中,RR的log(OR)对OS的log(HR)回归R2=0.32(95%CI 0.02-0.76;P=0.01)。
- 按疾病类型和免疫检查点抑制剂作用机制分层的预设分析显示,RR与非小细胞肺癌适应症的OS关联极弱。
- 预设分层分析显示,RR与细胞毒性T淋巴细胞相关抗原4(CTLA-4)抑制剂治疗的PFS关联中等。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To assess the role of the tumour response rate (RR) after immune checkpoint inhibitors-based therapy as a potential surrogate end-point of progression-free survival (PFS) and overall survival (OS) in patients with solid tumours, we performed a trial-based meta-regression of randomised studies comparing different immune checkpoint inhibitors-based treatments. METHODS: The systematic literature search included the electronic databases and the proceedings of oncologic meetings. Treatment effects on PFS and OS were expressed as hazard ratios (HRs); treatment effects on RR were expressed as odds ratios (ORs). A weighted regression analysis was performed on log-transformed treatment effect estimates to test the association between treatment effects on the surrogate outcome and treatment effects on the clinical outcome. RESULTS: Twenty-four trials, for a total of 11,894 patients, were included in the analysis. Using the complete set of data, the regression of either the log(HR) for PFS or the log(HR) for OS on the log(OR) for RR demonstrated weak associations (R2 = 0.47; 95% confidence interval [CI], 0.03-0.77; P = 0.001; and R2 = 0.32; 95% CI, 0.02-0.76; P = 0.01, respectively). The pre-planned analyses stratifying trials according to different type of disease and different mechanism of action of immune checkpoint inhibitors showed a very weak association of the RR with the OS for non-small cell lung cancer indicated and a modest association of the RR with the PFS for cytotoxic T lymphocyte-associated antigen 4 checkpoint inhibitors. CONCLUSION: The results of the trial-based meta-regression analysis indicated a weak correlation between RR and OS, supporting future investigations to assess the surrogacy of RR in the patient treated with immune checkpoint inhibitors.
引用
- Roviello G, Andre F, Venturini S, et al. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. Eur J Cancer. 2017. PMID: 29055841. doi:10.1016/j.ejca.2017.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。